Question 1

What is Prostamax?

Accepted Answer

According to PubMed-indexed literature, Prostamax is a synthetic short-chain peptide bioregulator with the sequence Lys-Glu-Asp-Pro (KEDP), one of the Khavinson-class 'cytogen' peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology and studied in the context of cellular aging and tissue-specific regulation. It is a Research Use Only compound.

Question 2

What has Prostamax actually been studied for in peer-reviewed work?

Accepted Answer

The small published record focuses mainly on epigenetic/chromatin observations in cultured lymphocytes from elderly donors (chromatin decondensation and ribosomal-gene activation) and on tissue-specific stimulation of rat tissue explants in organotypic culture. These are exploratory laboratory endpoints, not clinical outcomes, and no therapeutic effect is established.

Question 3

Is there human clinical trial evidence for Prostamax?

Accepted Answer

No randomized controlled human trials of the synthetic peptide (KEDP) are indexed in PubMed. Some work used lymphocytes from elderly subjects, but that is ex vivo cell-culture research rather than clinical efficacy testing. The evidence is best described as limited peer-reviewed data.

Question 4

How is Prostamax different from Prostatilen?

Accepted Answer

In the literature, Prostatilen denotes a natural polypeptide complex extracted from prostate tissue (a 'cytomedine'), whereas Prostamax is described as a defined synthetic peptide (KEDP, a 'cytogen'). They are conceptually related but are distinct preparations, so research on Prostatilen should not be assumed to apply to Prostamax.

Question 5

What mechanism do researchers propose for Prostamax?

Accepted Answer

Proposed mechanisms center on epigenetic regulation: short Lys/Glu/Asp-containing peptides are hypothesized to interact with chromatin and influence gene-expression accessibility (for example, chromatin decondensation), framed within Khavinson's 'peptide theory of aging.' These remain hypotheses drawn from small studies rather than established pharmacology.

Question 6

What does the research indicate about dosing?

Accepted Answer

There is no established or medically endorsed human dosing; research-reported amounts vary, and in vitro studies used nanogram-per-milliliter culture concentrations that do not translate to human use. For any protocol parameters, consult the specific cited study or a protocol reference. This is not medical advice.

Question 7

What observed effects appear in Prostamax research?

Accepted Answer

Published Prostamax studies are small and mechanistic (chromatin and tissue-culture endpoints) and do not constitute a safety dataset; the observed effects in research are limited to the cellular changes reported in vitro, and no rigorous human tolerability data specific to the synthetic peptide are indexed. It is Research Use Only and not for human use.

Phase	Daily reference amount	Units / volume
Weeks 1–2	500 mcg (0.5 mg)	5 units (0.05 mL)
Weeks 3–4	750 mcg (0.75 mg)	7.5 units (0.075 mL)
Weeks 5–8	1,000 mcg (1 mg)	10 units (0.10 mL)
Weeks 9–12 (optional extension)	1,000 mcg (1 mg)	10 units (0.10 mL)

Prostamax.

Calculated volume reference

Cited protocol & reconstitution guide